Andrew R. de Guttadauro
President bij Oncolytics Biotech (U.S.), Inc.
Vermogen: 11 140 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Kirk Look | M | - |
Oncolytics Biotech (U.S.), Inc.
 Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Part of Oncolytics Biotech, Inc., Oncolytics Biotech (U.S.), Inc. manufactures pharmaceutical products. The company is based in Half Moon Bay, CA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Ronald B. Moss | M | 64 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 jaar |
| Mary Ann Dillahunty | F | - |
Oncolytics Biotech (U.S.), Inc.
Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Part of Oncolytics Biotech, Inc., Oncolytics Biotech (U.S.), Inc. manufactures pharmaceutical products. The company is based in Half Moon Bay, CA. | - |
| Richard Kenney | M | 66 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 4 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Andrew R. de Guttadauro
- Persoonlijk netwerk
